production
Skip to Content

MT5502: DRUG DEVELOPMENT TO EVIDENCE BASED MEDICINE (2014-2015)

Last modified: 28 Jun 2018 10:27


Course Overview

None.

Course Details

Study Type Postgraduate Level 5
Session Second Sub Session Credit Points 20 credits (10 ECTS credits)
Campus None. Sustained Study No
Co-ordinators
  • Dr James McLay

What courses & programmes must have been taken before this course?

None.

What other courses must be taken with this course?

None.

What courses cannot be taken with this course?

None.

Are there a limited number of places available?

No

Course Description

Impact or particular disease states with reference to the pathophysiology, epidemiology, economic cost and current drugs available. Rationale for further drug development and clinical trials. End point measurements. Drug trial design. Critical analysis of 'key' publications on the treatment of disease. Clinical guidelines. Selecting a limited list of medicines. Pharmacovigilance. Ethics. Development of a new medicinal compound from pharmacology to pharmaceutical product.

Contact Teaching Time

Information on contact teaching time is available from the course guide.

Teaching Breakdown

More Information about Week Numbers


Details, including assessments, may be subject to change until 31 August 2023 for 1st half-session courses and 22 December 2023 for 2nd half-session courses.

Summative Assessments

2 assignments each comprising a presentation (2x 10%) and an essay (2x 25%) and 1 general essay (30%)

Formative Assessment

There are no assessments for this course.

Feedback

None.

Course Learning Outcomes

None.

Compatibility Mode

We have detected that you are have compatibility mode enabled or are using an old version of Internet Explorer. You either need to switch off compatibility mode for this site or upgrade your browser.